Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Leidos Holdings heads into its November 3 results with analysts trimming targets and the stock down 12% over the past month, creating a widening gap between where the Street thinks the shares should trade and where the market has taken them.
The most striking feature of the past two sessions is the cluster of analyst target cuts. Citigroup's John Godyn, who holds a Buy rating, cut his target from $161 to $141 on October 7, just one day after Jefferies lowered its Hold target from $145 to $130 and TD Cowen trimmed from $135 to $130. All three kept their ratings unchanged. The consensus mean target now sits at $153.27 against a close of $116.69, implying roughly 31% upside on paper. But the direction of travel is what matters here: targets have been falling, not rising. Bank of America was the lone voice moving the other way, nudging its Neutral target from $125 to $135 in mid-September, but Goldman Sachs had already cut from $152 to $132 in August. The overwhelming message from the Street is that estimates peaked post the August earnings beat and are being walked back.
The bear case is well-understood. Government services businesses live or die on federal appropriations, and Leidos faces the dual risk of congressional budget uncertainty and execution pressure on fixed-price development programmes. Operating income declined in the Health, Homeland, and Defense segments in the most recent quarter even as headline adjusted EPS of $3.13 beat expectations. Bulls counter with $9 billion in defense tech awards over the past 15 months, a 31% jump in funded backlog from the Entrust acquisition, and management's 6% revenue growth outlook for 2026. The valuation is undemanding: the stock trades at a P/E of roughly 9.2 and EV/EBITDA of 7.7, both having compressed notably over the past 30 days as the price fell. The EV/EBIT factor ranks in the 88th percentile, a signal that by earnings-yield metrics the stock looks cheap relative to the broader universe.
Short interest tells a secondary story, but one worth noting. Bears have been adding over the past month, with short interest up 20% over 30 days to 3.7% of the free float. The one-week rise of 7% is the sharpest move in the series shown, and Tuesday saw an 8.5% single-day jump in estimated short shares. At 3.7% of float, the position is not extreme, and the borrow market is far from stressed: availability is at 2,991%, meaning there are roughly 30 shares available to borrow for every one already out on loan. Borrowing costs at 0.59% are low by any standard, even after nearly doubling in one session on October 6. The short score has ticked up to 37.1 from 33.7 two weeks ago, but remains in a moderate range. The picture is one of incremental short building, not a crowded bear trade.
Options positioning adds a mild contrarian note. The put/call ratio has drifted to 0.47, fractionally below its 20-day average of 0.49 and well off the 52-week high of 1.40 seen earlier in the year. A PCR below its own mean, even as the stock sells off, suggests options traders are not rushing to buy protection. The z-score of minus 0.54 is negligible. If anything, the options market looks more complacent than the price action warrants.
Peer weakness adds some context. CACI fell 3.9% on October 6 alone and was down 1.4% on the week. Booz Allen Hamilton dropped 0.7% on the day and 2.3% on the week. Both had a rough session, though neither matched Leidos's 5.2% weekly drawdown. Amentum Holdings was the outlier, gaining 3.4% on the week, suggesting the selling in the government services space is stock-specific rather than purely sector-driven.
The insider register carries a minor footnote. September 30 saw a batch of small share awards (transaction code A) to the CFO, general counsel, and several sector presidents. These are compensation mechanics, not conviction buys, and the 90-day net position across all insiders is negative $1.5 million, driven by open-market sales in August at prices around $140 to $141. Directors sold at levels well above where the stock trades today.
The last earnings print on August 4 produced a one-day gain of 6.8% and a five-day gain of 18.7%, a reminder that Leidos has rewarded patience after results before. Whether November 3 resembles that pattern or whether the analyst target cuts are front-running disappointment in the underlying business is the question the market will price over the next 27 days.
See the live data behind this article on ORTEX.
Open LDOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
